Drug Trial Radar · NCT06389292
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
486
Planned (sponsor's estimate)
Start
Jun 11, 2024
Primary completion
May 25, 2028
Study completion Mar 26, 2029
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A global, multicenter, randomized, double-blind, placebo-controlled, phase III pivotal registration study, to evaluate the efficacy of APG-2575 (Lisaftoclax) combined with azacitidine (AZA) versus placebo combined with azacitidine in newly diagnosed acute myeloid leukemia who are not eligible for standard induction chemotherapy.
Conditions
- Acute Myeloid Leukemia
Interventions
APG-2575(Lisaftoclax )Drug
QD, oral administration, every 28 days for a dosing cycle.
PlaceboOther
QD, oral administration, every 28 days for a dosing cycle.
Azacitidine InjectionDrug
QD, subcutaneous or intravenous injection, D1-7 in 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival(OS)Time frame: Up to 5 years
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Hematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Moscow Multidisciplinary Clinical Center "Kommunarka"
Moscow, Russia · Recruiting
Botkin Moscow Multidisciplinary Research and Clinical Center
Moscow, Russia · Recruiting
Russian Research Institute of Hematology and Transfusiology of the Federal Medical and Biological Agency
Saint Petersburg, Russia · Recruiting
Leningrad Regional Clinical Hospital
Saint Petersburg, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.